Mason Street Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Mason Street Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-44,630	Closed	-$1.96M	–	1688
2014 Q4	$1.96M	Hold	44,630	–	–	0.01%	964
2014 Q3	$2.53M	Buy	+44,630	New	+$2.25M	0.02%	825

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Mason Street Advisors's RARE Position: Q1 2015 in Review

Mason Street Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2015, closing a stake of 44,630 shares — an estimated $1.96M sold.

Mason Street Advisors first reported a position in RARE in Q3 2014 and held it in 2 quarters. The position peaked at $2.53M in Q3 2014. 126 funds tracked by Wall St. Rank hold RARE as of Q1 2015.

Mason Street Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q1 2015 after selling out during the quarter.
Mason Street Advisors sold 44,630 Ultragenyx Pharmaceutical shares in Q1 2015, an estimated $1.96M.
Mason Street Advisors first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and held it in 2 quarters.
Mason Street Advisors's Ultragenyx Pharmaceutical position peaked at $2.53M in Q3 2014.
126 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2015.

Based on Mason Street Advisors's 13F filing for Q1 2015, filed 15 May 2015.